Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | PPARG | P37231 | 18/20 | 0.60 |
| ▸ | PPARA | Q07869 | 17/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171344 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL8935859 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL11550284 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL4257140 | 0.86 | PPARG (0.65) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL29217238 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL11128486 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL21991991 | 0.85 | PPARG (0.66) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL1745447 | 0.85 | PPARG (0.66) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL433427 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL9656236 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340168-A1 | OXA-SPIRODIPHOSPHINE LIGAND AND METHOD FOR ASYMMETRIC HYDROGENATION OF alpha, beta-UNSATURATED CARBOXYLIC ACIDS | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340168-A1 | OXA-SPIRODIPHOSPHINE LIGAND AND METHOD FOR ASYMMETRIC HYDROGENATION OF alpha, beta-UNSATURATED CARBOXYLIC ACIDS | OXER1, NR1H3, OXGR1 | SMN1; SMN2 4153/4885PPARG 300/4885PPARA 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.